FDA's 45-day TV ad review "shot clock" in guidance

Share this article:
TV ads for most prescription drugs must be submitted to FDA for pre-review 45 days before the manufacturer intends to air them, according to an FDA draft guidance in tomorrow's Federal Register.

The guidance isn't a bolt from the blue but rather a case of the agency catching up on old business – in this case, a clause in the 2007 FDA Amendments Act (FDAAA) authorizing the agency to “require the submission of any television advertisement for a drug … not later than 45 days before dissemination of the television advertisement.”

The agency specified six categories of drugs for which TV ads must be submitted 45 days in advance, including those for new drugs, for drugs with Risk Evaluation and Mitigation Strategies, for Schedule II controlled substances, etc. – in short, for most any prescription drug. The 45-day review “clock” would start when CDER or CBER recieves a complete review package, including annotated storyboards and other materials.

What happens if agency reviewers can't get to it before the scheduled air date?

“FDA will notify the sponsor if the Agency is not able to provide comments within the 45 calendar day time frame,” said the draft guidance. “FDA's notification will include an estimate of the date on which FDA expects to provide its comments. In such situations, the sponsor should determine whether it will wait for FDA's comments before disseminating the TV ad or whether it will disseminate the TV ad without waiting for FDA's comments. The sponsor should notify FDA of its decision. Once the 45-day review time has elapsed, there is no specific legal consequence resulting from disseminating the proposed TV ad without waiting for FDA's comments.” The agency will discontinue its review in that instance, the guidance said.

Violators may be subject to criminal penalties, the agency said, and failure to comply will be factored into any penalties for advertising found to be in violation of the FD&C Act.

The devil will be in the details, said Coalition for Healthcare Communication executive director John Kamp, but the proposed rule change isn't good news for the industry.

“This guidance creates an FDA ‘shot clock' that doesn't allow you to take a shot at broadcast marketing for an additional 45 days,” said Kamp. “And unfortunately, there's no ‘overtime' tacked on at the end of the patent period to recoup the lost sales opportunity.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...